CD274 and neoplasm: In this tumor “heating” scenario, anti-PD-1 therapies can then exert their full function, blocking the tumor’s second line of defense (the PD-1/PD-L1 interaction) and unleashing a robust anti-tumor immune response to eliminate cancer cells [6,68].